CRI Report: next-generation gynecological cancer diagnostics market to be $5.66 billion in 2031

According to a new market intelligence report by Our Research Team titled “Next-Generation Gynecological Cancer Diagnostics Market – A Global Market and Regional Analysis: Focus on Technology, Product Type, End User, and Country Analysis – Analysis and Forecast, 2020-2031”, the global next-generation gynecological cancer diagnostics market was valued at $1.98 billion in 2020 and is expected to be $5.66 billion in 2031.

The comprehensive study of the global next-generation gynecological cancer diagnostics by Our Research Team extensively covers the following:

• Market numbers as well as market volume on micro-segments that are influencing the market growth
• In-depth analysis and markets number for five exclusive segmentation of the market, namely, by product type, by indication, by technology, by end user, and by region
• 100+ products and services offered by key companies of the market
• Data of 100+ products and services mapped by product type, technology, and by indication
• In-depth research on the regulatory scenario, funding scenario, and reimbursement policies for the major countries of the global next-generation gynecological cancer diagnostics market
• Detailed landscape of reimbursement policies and funding scenario
• Detailed global and regional market share analysis, including the scrutiny of more than ten countries
• Market share analysis for 15 key public companies and growth share analysis by platform
• Study of data of more than 42 companies

Besides these parameters, the study also encompasses the market growth drivers, opportunities, market restraining factors, competition mapping, segmental analysis, and regional analysis.

This market intelligence report provides a multi-dimensional view of the global next-generation gynecological cancer diagnostics market in terms of market size and growth potential. This research report aims at answering various aspects of the global next-generation gynecological cancer diagnostics market with the help of the key factors driving the market, threats that can inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of market expansion.

Furthermore, the competitive landscape chapter in the report presents the competitive nature of the global market and enables the reader to get acquainted with the recent market activities, such as product launches, partnerships, and product approvals. The research report provides a comprehensive analysis of the product sales, manufacturers, and trend analysis by segment and by region.

The global next-generation gynecological cancer diagnostics market is expected to witness high growth, attributing to the increasing burden of gynecological cancer, rising uptake of cancer research projects across the globe, growing awareness about personalized medicine, and decreasing cost of sequencing. The continued significant investments by healthcare companies to meet industry demand and the growing adoption of next-generation gynecological cancer testing among major end users for the identification of underlying mutations are the major factors propelling the growth of the global next-generation gynecological cancer diagnostics market.

Albeit well-established methods, such as polymerase chain reaction (PCR), microarray, and traditional sequencing, continue to be employed for mutation analysis due to their conventional reliability, recent advancements in cancer genome sequencing technologies have revolutionized the approach for applications in gynecological cancer diagnosis. The emergence of next-generation sequencing (NGS) technology has risen to the forefront and has provided an enhanced molecular profiling ability for gathering clinical insights for cancer diagnosis, prognosis, and therapeutic discoveries.

Companies developing assays or panels based on next-generation sequencing (NGS) are now offering high throughput with a faster turnaround time of around three weeks, thereby facilitating its demand in the field of gynecological cancer mutation analysis. With advancements in technology, the sequencing landscape in the global gynecological cancer diagnostics market is undergoing rapid transformation.

According to Sara Virmani, Research Analyst at Our Research Team, “North America is the leading contributor to the global next-generation gynecological cancer diagnostics market. The contribution of North America to the global next-generation gynecological cancer diagnostics market was valued at approximately 42.50% in 2020. The North America next-generation gynecological cancer diagnostics market is anticipated to be primarily driven by various technological innovations to advance and enhance the overall scope of genetic testing. Various research and development exercises, investments by biopharmaceuticals and biotechnology companies in the fields of genetic testing, molecular research, and clinical research are promoting the development of next-generation diagnostic products and services. In addition, NCCN Clinical Practice Guidelines in Oncology, Center for Medicare & Medicaid Services (CMS), and food and drug administration (FDA) have been regulating guidelines facilitating larger adoption of genetic testing in ovarian, cervical, and uterine cancer. However, Asia-Pacific is expected to grow at an impressive CAGR of 12.39% during the forecast period 2021-2031.”

Key insights are drawn from in-depth interviews with the key opinion leaders of more than 20 leading companies, market participants, and vendors. This report is a meticulous compilation of research on more than 15 players in the market ecosystem and profiles 15 companies, including several key players, namely Agilent Technologies, Inc., BGI, CENTOGENE N.V., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Illumina, Inc., Laboratory Corporation of America Holdings, Konica Minolta, Inc., Qiagen N.V., ARUP Laboratories, Quest Diagnostics Incorporated, Myriad Genetics, Inc., Invitae Corporation, Opko Health, Inc., and Fulgent Genetics, Inc.

The study also offers strategic recommendations that can help organizations in tracking various products, trends, and technologies that are changing the dynamics of the market. The recommendations by Our Research Team also offer bespoke research services to help organizations meet their objectives.

Who should buy this report?

• Manufacturers of next-generation gynecological cancer tests
• Molecular diagnostics manufacturer in gynecology
• Service providers and end users of next-generation gynecological cancer diagnostics

How can market intelligence on the global next-generation gynecological cancer diagnostics market add value to an organization’s decision-making process?

• Aid in next-generation gynecological cancer diagnostics products and services development and understanding the competitive landscape of the global market
• Help in targeting a segment for launching a new product
• Offer go-to-market strategies for the different source type
• Support in diversifying the product portfolio based on indication (ovarian, cervical, and uterine cancer) and technology (polymerase chain reaction (PCR), next-generation sequencing (NGS), and others)
• Help in analyzing technological substitutes and comparing the specification
• Aid in understanding the end-user requirement
• Assist in exploring the newer application and methods
• Aid in understanding the impact of the COVID-19 outbreak on the market

Insightful Questions Covered to Enable Companies Take Strategic Decisions

• Which gynecological cancers have been considered in the report?
• What are the key milestones in the development of next-generation gynecological cancer diagnostics?
• What is the scope of next-generation gynecological cancer diagnostics in the future?
• What are the major market drivers, restraints, and opportunities in the global next-generation gynecological cancer diagnostics market?
• What are the key developmental strategies that are being implemented by the key players to sustain this market?
• What is the impact of COVID-19 on the next-generation gynecological cancer diagnostics market?
• What are the guidelines implemented by different government bodies to regulate the approval of next-generation gynecological cancer diagnostics panels and assays?
• How are next-generation gynecological cancer diagnostics being utilized for the development of personalized medicine?
• What is the role of biomarkers in next-generation gynecological cancer diagnostics?
• How will the investments by public and private companies and government organizations affect the global next-generation gynecological cancer diagnostics market?
• What was the market size of the leading segments and sub-segments of the global next-generation gynecological cancer diagnostics market in 2020?
• How will the industry evolve during the forecast period 2021-2031?
• What will be the growth rate of the next-generation gynecological cancer diagnostics market during the forecast period 2021-2031?
• How will each of the segments of the global next-generation gynecological cancer diagnostics market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2031?
• What is the market size of the next-generation gynecological cancer diagnostics market in different countries of the world?
• Which region is expected to contribute to the highest sales of the next-generation gynecological cancer diagnostics market?
• What are the reimbursement scenarios and regulatory structures for the next-generation gynecological cancer diagnostics market in different regions?
• What are the key strategies incorporated by the players of the global next-generation gynecological cancer diagnostics market to sustain the competition and retain their supremacy?
Buy the report: Next-Generation Gynecological Cancer Diagnostics Market – A Global Market and Regional Analysis: Focus on Technology, Product Type, End User, and Country Analysis – Analysis and Forecast, 2020-2031